IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case report
Abstract Background The flare of immune-mediated disease following coronavirus disease of 2019 (COVID-19) vaccination is a rare adverse event following immunization. De novo, as well as relapsing IgA nephropathy (IgAN) cases, have been reported following either mRNA-1273 (Moderna) or BNT162b2 (Pfize...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-04-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-022-02769-9 |
| _version_ | 1819022650500972544 |
|---|---|
| author | Shota Watanabe Shuling Zheng Arash Rashidi |
| author_facet | Shota Watanabe Shuling Zheng Arash Rashidi |
| author_sort | Shota Watanabe |
| collection | DOAJ |
| description | Abstract Background The flare of immune-mediated disease following coronavirus disease of 2019 (COVID-19) vaccination is a rare adverse event following immunization. De novo, as well as relapsing IgA nephropathy (IgAN) cases, have been reported following either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) vaccination. To our knowledge, the majority of IgAN relapses did not result in severe acute kidney injury (AKI) and resolved spontaneously. Case presentation This is a case of a 54-year-old female with a previous diagnosis of IgAN who developed IgAN relapse following the second dose of Moderna vaccine. Gross hematuria developed 2 days after vaccination, which was accompanied by significant AKI. Kidney biopsy showed mild tubular atrophy and IgA staining in mesangium without crescent formation. Significant improvement in serum creatinine (Cr) was observed on day 10 after initiating prednisone. Cr came back to normal within 3 months after initiating corticosteroid. Conclusion COVID-19 vaccination is associated with a flare of IgAN that may cause significant AKI. Steroid therapy is associated with recovery. IgAN flare after COVID-19 vaccination should be closely monitored to elucidate any adverse effect associated with the novel vaccine. |
| first_indexed | 2024-12-21T04:26:22Z |
| format | Article |
| id | doaj.art-2bed28f1713147149e522d327b1a0cbf |
| institution | Directory Open Access Journal |
| issn | 1471-2369 |
| language | English |
| last_indexed | 2024-12-21T04:26:22Z |
| publishDate | 2022-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Nephrology |
| spelling | doaj.art-2bed28f1713147149e522d327b1a0cbf2022-12-21T19:16:03ZengBMCBMC Nephrology1471-23692022-04-012311410.1186/s12882-022-02769-9IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case reportShota Watanabe0Shuling Zheng1Arash Rashidi2Internal Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve UniversityPathology, University Hospitals Cleveland Medical CenterNephrology, University Hospitals Cleveland Medical CenterAbstract Background The flare of immune-mediated disease following coronavirus disease of 2019 (COVID-19) vaccination is a rare adverse event following immunization. De novo, as well as relapsing IgA nephropathy (IgAN) cases, have been reported following either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) vaccination. To our knowledge, the majority of IgAN relapses did not result in severe acute kidney injury (AKI) and resolved spontaneously. Case presentation This is a case of a 54-year-old female with a previous diagnosis of IgAN who developed IgAN relapse following the second dose of Moderna vaccine. Gross hematuria developed 2 days after vaccination, which was accompanied by significant AKI. Kidney biopsy showed mild tubular atrophy and IgA staining in mesangium without crescent formation. Significant improvement in serum creatinine (Cr) was observed on day 10 after initiating prednisone. Cr came back to normal within 3 months after initiating corticosteroid. Conclusion COVID-19 vaccination is associated with a flare of IgAN that may cause significant AKI. Steroid therapy is associated with recovery. IgAN flare after COVID-19 vaccination should be closely monitored to elucidate any adverse effect associated with the novel vaccine.https://doi.org/10.1186/s12882-022-02769-9COVID-19 vaccineIgA nephropathyAKIHematuriaKidney biopsy |
| spellingShingle | Shota Watanabe Shuling Zheng Arash Rashidi IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case report BMC Nephrology COVID-19 vaccine IgA nephropathy AKI Hematuria Kidney biopsy |
| title | IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case report |
| title_full | IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case report |
| title_fullStr | IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case report |
| title_full_unstemmed | IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case report |
| title_short | IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case report |
| title_sort | iga nephropathy relapse following covid 19 vaccination treated with corticosteroid therapy case report |
| topic | COVID-19 vaccine IgA nephropathy AKI Hematuria Kidney biopsy |
| url | https://doi.org/10.1186/s12882-022-02769-9 |
| work_keys_str_mv | AT shotawatanabe iganephropathyrelapsefollowingcovid19vaccinationtreatedwithcorticosteroidtherapycasereport AT shulingzheng iganephropathyrelapsefollowingcovid19vaccinationtreatedwithcorticosteroidtherapycasereport AT arashrashidi iganephropathyrelapsefollowingcovid19vaccinationtreatedwithcorticosteroidtherapycasereport |